Exhibit 99.1

 

 

CELGENE REPORTS THIRD QUARTER 2018

OPERATING AND FINANCIAL RESULTS

 

–    Total net product sales of $3,890 million, increased 18% Y/Y

 

–    Raising full-year total revenue guidance to ~$15.2 billion and OTEZLA® net product sales to ~$1.6 billion

 

–    Showcasing our next-generation pipeline across multiple disease areas at ASH

 

–    Appointed Dr. Alise Reicin as President of Global Clinical Development

 

SUMMIT, NJ — (October 25, 2018) — Celgene Corporation (NASDAQ: CELG) reported net product sales of $3,890 million for the third quarter of 2018, an 18 percent increase from the same period in 2017. Celgene reported third quarter 2018 total revenue of $3,892 million, an 18 percent increase compared to $3,287 million in the third quarter of 2017.

 

Based on U.S. GAAP (Generally Accepted Accounting Principles), Celgene reported net income of $1,082 million and diluted earnings per share (EPS) of $1.50 for the third quarter of 2018. For the third quarter of 2017, GAAP net income was $988 million and diluted EPS was $1.21.

 

Adjusted net income for the third quarter of 2018 increased 6 percent to $1,645 million compared to $1,555 million in the third quarter of 2017. For the same period, adjusted diluted EPS increased 20 percent to $2.29 from $1.91.

 

“Excellent top- and bottom-line momentum in the third quarter supports raising our 2018 financial guidance,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation. “We are focused on shaping Celgene’s future by rapidly advancing our late-stage pipeline, accelerating promising early research programs, and strengthening the organization.”

 

Third Quarter 2018 Financial Highlights

 

Unless otherwise stated, all comparisons are for the third quarter of 2018 compared to the third quarter of 2017. The adjusted operating expense categories presented below exclude share-based employee compensation expense and collaboration-related upfront expense. Please see the attached Use of Non-GAAP Financial Measures and Reconciliation of GAAP to Adjusted Net Income for further information relevant to the interpretation of adjusted financial measures and

 


 

reconciliations of these adjusted financial measures to the most comparable GAAP measures, respectively.

 

Net Product Sales Performance

 

·                                          REVLIMID® sales for the third quarter increased 18 percent to $2,449 million. REVLIMID® sales growth was driven by increases in market share and extended treatment duration. U.S. sales of $1,667 million and international sales of $782 million increased 22 percent and 9 percent year-over-year, respectively.

·                                          POMALYST®/IMNOVID® sales for the third quarter were $513 million, an increase of 23 percent year-over-year. POMALYST®/IMNOVID® sales growth was driven primarily by increases in market share and treatment duration. U.S. sales were $357 million and international sales were $156 million, an increase of 33 percent and 5 percent year-over-year, respectively.

·                                          OTEZLA® sales for the third quarter were $432 million, a 40 percent increase year-over-year. Third quarter U.S. sales of $348 million and international sales of $84 million increased 39 percent and 45 percent year-over-year, respectively. OTEZLA® sales growth in the U.S. was driven by increases in demand with continued benefit from expanded market access and higher channel inventory levels. OTEZLA® international sales have maintained solid momentum in key ex-U.S. markets including France and Japan.

·                                          ABRAXANE® sales for the third quarter were $288 million, a 15 percent increase year-over-year. ABRAXANE® sales growth was driven by increases in demand and customer buying patterns. U.S. sales were $174 million and international sales were $114 million, an increase of 17 percent and 12 percent year-over-year, respectively.

·                                          In the third quarter, all other product sales, which include IDHIFA®, THALOMID®, ISTODAX®, VIDAZA® and an authorized generic version of VIDAZA® drug product primarily sold in the U.S., were $208 million compared to $226 million in the third quarter of 2017.

 

Research and Development (R&D)

 

On a GAAP basis, R&D expenses were $1,081 million for the third quarter of 2018 compared to $1,347 million for the same period in 2017. Adjusted R&D expenses were $948 million for the third quarter of 2018 compared to $698 million for the third quarter of 2017. The current period included an increase in R&D expense associated with the acquisition of Juno Therapeutics (Juno) and regulatory submission-related work on multiple programs. Additional R&D expenses (only included on a GAAP basis) decreased in 2018, as outlined in the attached Reconciliation of GAAP to Adjusted Net Income.

 

Selling, General and Administrative (SG&A)

 

On a GAAP basis, SG&A expenses were $746 million for the third quarter of 2018 compared to $608 million for the same period in 2017. Adjusted SG&A expenses were $642 million for the

 


 

third quarter of 2018 compared to $521 million for the third quarter of 2017. The current period included an increase in SG&A expense associated with the acquisition of Juno and marketing-related expenses. Additional SG&A expense (only included on a GAAP basis) increased in 2018, as outlined in the attached Reconciliation of GAAP to Adjusted Net Income.

 

Cash, Cash Equivalents, Marketable Debt Securities and Publicly-Traded Equity Securities

 

Operating cash flow was $1.9 billion in the third quarter of 2018, compared to $1.1 billion for the third quarter of 2017. In the third quarter, Celgene received approximately 6 million of its shares upon final settlement of the accelerated share repurchase (ASR) program, which commenced during the second quarter of 2018. The total number of shares repurchased under the ASR agreement was approximately 24.0 million at a weighted average price of $83.53 per share. Celgene ended the quarter with approximately $4.4 billion in cash, cash equivalents, marketable debt securities and publicly-traded equity securities.

 

Celgene Expects Volume-Driven Product Sales and Earnings Growth in 2018

 

 

 

Previous 2018 Guidance

 

Updated 2018 Guidance

Total Revenue

 

~$15.0B

 

~$15.2B

REVLIMID® Net Product Sales

 

~ $9.7B

 

Unchanged

POMALYST®/IMNOVID® Net Product Sales

 

~ $2.0B

 

Unchanged

OTEZLA® Net Product Sales

 

~$1.5B

 

~$1.6B

ABRAXANE® Net Product Sales

 

~$1.0B

 

Unchanged

GAAP Operating Margin

 

~ 35%

 

~34%

GAAP Diluted EPS

 

$5.95-$6.25

 

$5.25-$5.75

Adjusted Operating Margin

 

~56.0%

 

~55.5%

Adjusted Diluted EPS

 

$8.70-$8.75

 

$8.75-$8.80

Adjusted Tax Rate

 

~17%

 

Unchanged

Weighted Average Diluted Shares

 

~735M

 

Unchanged

 

Portfolio Updates

 

·                  At the 2018 American Society of Hematology (ASH) annual meeting in December, expected data presentations include:

·                  In collaboration with partner Acceleron Pharma, data from the phase III MEDALISTand BELIEVE trials with luspatercept in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia, respectively;

·                  Data from the phase I TRANSCEND CLL-004 trial evaluating liso-cel (JCAR017) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL);

·                  In collaboration with partner bluebird bio, data from the phase I trial evaluating bb21217 in patients with relapsed and/or refractory multiple myeloma (RRMM);

·                  Data from the phase I/II EVOLVE trial evaluating JCARH125 in patients with RRMM; and,

 


 

·                  Data from the phase III AUGMENT trial evaluating REVLIMID® in combination with rituximab (R²) in patients with relapsed and/or refractory indolent non-Hodgkin lymphoma (NHL).

·                  The phase III COMMANDS front-line trial evaluating luspatercept in erythropoiesis-stimulating agent (ESA)-naïve, very low, low or intermediate risk MDS patients initiated in the third quarter.

·                  In collaboration with partner bluebird bio, the clinical program evaluating bb2121 in earlier lines of multiple myeloma is advancing, including the phase II MM-002 and phase III MM-003 trials.

·                  In October, Celgene announced results from a phase II/III cooperative group study (ECOG E3A06) conducted by the National Cancer Institute in conjunction with the ECOG-ACRIN Cancer Research Group. In the study, single-agent REVLIMID® achieved a statistically significant improvement in the primary endpoint of progression-free survival compared to observation in patients with smoldering myeloma. Data from the ECOG E3A06 study will be presented at a future medical meeting.

·                  At the European Society for Medical Oncology (ESMO) 2018 congress in October, efficacy and safety data were presented for the first time from the Genentech-sponsored phase III IMpassion130 trial evaluating TECENTRIQ® (atezolizumab) in combination with ABRAXANE® in patients with previously untreated metastatic triple-negative breast cancer. These data were simultaneously published in The New England Journal of Medicine. In addition, data were presented from the Genentech-sponsored phase III IMpower130 trial evaluating first-line treatment of TECENTRIQ® plus chemotherapy (carboplatin and ABRAXANE®) in patients with stage IV non-squamous non-small cell lung cancer (NSCLC).

·                  In October, Celgene announced that the phase III STYLE trial evaluating OTEZLA® in patients with moderate to severe plaque psoriasis of the scalp achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response at week 16 compared with placebo. In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole-body itch numeric rating scale (NRS) at week 16 with OTEZLA® versus placebo. The safety profile for OTEZLA® in the STYLE study was generally consistent with the known safety profile of OTEZLA®, and no new safety signals were identified. Additionally, the phase III ADVANCE trial evaluating OTEZLA® in patients with mild to moderate plaque psoriasis is on track to initiate by year-end 2018.

·                  In October, data from the phase II HEROES trial evaluating RPC4046 in patients with eosinophilic esophagitis (EoE) were presented at the United European Gastroenterology Week (UEGW) conference. Data from the HEROES trial demonstrated that reductions in average esophageal eosinophil count observed at week 16 in patients treated with RPC4046 (primary endpoint) were sustained through an additional 52 weeks of treatment in an open-label extension study.

 


 

Organizational Updates

 

·                  Celgene appointed Dr. Alise Reicin as President, Global Clinical Development, effective November 1, 2018.

·                  Celgene appointed Aijaz “Jazz” Tobaccowalla as Senior Vice President, Chief Digital & Information Officer, effective August 27, 2018.

 

Third Quarter 2018 Conference Call and Webcast Information

 

Celgene will host a conference call to discuss the third quarter of 2018 operational and financial performance on Thursday, October 25, 2018, at 9 a.m. ET.  The conference call will be available by webcast at http://www.celgene.com. An audio replay of the call will be available from noon October 25, 2018, until midnight ET November 1, 2018.  To access the replay in the U.S., dial (855) 859-2056; outside the U.S. dial (404) 537-3406.  The participant passcode is 5516848.

 

About Celgene

 

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.  For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

 

About REVLIMID®

 

In the U.S., REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma. REVLIMID® as a single agent is also indicated as a maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplant. REVLIMID® is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.  REVLIMID® is approved in the U.S. for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.  Limitations of Use: REVLIMID® is not indicated and is not recommended for the treatment of chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

 

About ABRAXANE®

 

In the U.S., ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.  Prior therapy should have included an anthracycline unless clinically contraindicated.  ABRAXANE® is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.  ABRAXANE® is also indicated for the first-

 


 

line treatment of metastatic adenocarcinoma of the pancreas in combination with gemcitabine.

 

About POMALYST®

 

In the U.S., POMALYST® (pomalidomide) is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

 

About OTEZLA®

 

In the U.S., OTEZLA® (apremilast) is indicated for the treatment of adult patients with active psoriatic arthritis.  OTEZLA® is indicated in the U.S. for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

 

Forward-Looking Statement

 

This press release contains forward-looking statements, which are generally statements that are not historical facts.  Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions.  Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made.  We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law.  Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control.  Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

 

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

 

Celgene

Investors:

908-673-9628

ir@celgene.com

or

Media:

908-673-2275

media@celgene.com

 


 

Use of Non-GAAP Financial Measures

 

In addition to financial information prepared in accordance with U.S. GAAP, this document also contains certain non-GAAP financial measures based on management’s view of performance including:

 

·                  Adjusted research and development expense

·                  Adjusted selling, general and administrative expense

·                  Adjusted operating margin

·                  Adjusted net income

·                  Adjusted earnings per share

 

Management uses such measures internally for planning and forecasting purposes and to measure the performance of the Company. We believe these adjusted financial measures provide useful and meaningful information to us and investors because they enhance investors’ understanding of the continuing operating performance of our business and facilitate the comparison of performance between past and future periods. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. When preparing these supplemental non-GAAP financial measures we typically exclude certain GAAP items that management does not consider to be normal, recurring cash operating expenses but that may not meet the definition of unusual or non-recurring items. Other companies may define these measures in different ways. The following categories of items are excluded from adjusted financial results:

 

Acquisition and Divestiture-Related Costs:  We exclude the impact of certain amounts recorded in connection with business combinations and divestitures from our adjusted financial results that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. These amounts may include non-cash items such as the amortization of acquired intangible assets, amortization of purchase accounting adjustments to inventories, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of contingent consideration and success payments. We also exclude transaction and certain other cash costs associated with business acquisitions and divestitures that are not normal, recurring operating expenses, including severance costs which are not part of a formal restructuring program.

 

Share-Based Compensation Expense:  We exclude share-based compensation from our adjusted financial results because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued.

 

Collaboration-Related Upfront Expenses:  We exclude collaboration-related upfront expenses from our adjusted financial results because we do not consider them to be normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. Upfront payments to collaboration partners are made at the commencement of a relationship anticipated to continue for a multi-year period and provide us with intellectual property rights, option rights and other rights with respect to particular programs. The variability of amounts and lack of predictability of collaboration-related upfront expenses makes the identification of trends in our ongoing research and development activities more difficult. We believe the presentation of adjusted research and development, which does not include collaboration-related upfront expenses, provides useful and meaningful information about our ongoing research and development activities by enhancing investors’ understanding of our normal, recurring operating research and development expenses and facilitates comparisons between periods and with respect to projected performance. All expenses incurred subsequent to the initiation of the collaboration arrangement, such as research and development cost-sharing expenses/reimbursements and milestone payments up to the point of regulatory approval are considered to be normal, recurring operating expenses and are included in our adjusted financial results.

 

Research and Development Asset Acquisition Expense:  We exclude costs associated with acquiring rights to pre-commercial compounds because we do not consider such costs to be normal, recurring operating expenses

 


 

due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. Research and development asset acquisition expenses includes expenses to acquire rights to pre-commercial compounds from a collaboration partner when there will be no further participation from the collaboration partner or other parties. The variability of amounts and lack of predictability of research and development asset acquisition expenses makes the identification of trends in our ongoing research and development activities more difficult. We believe the presentation of adjusted research and development, which does not include research and development asset acquisition expenses, provides useful and meaningful information about our ongoing research and development activities by enhancing investors’ understanding of our normal, recurring operating research and development expenses and facilitates comparisons between periods and with respect to projected performance.

 

Restructuring Costs:  We exclude costs associated with restructuring initiatives from our adjusted financial results. These costs include amounts associated with facilities to be closed, employee separation costs and costs to move operations from one location to another. We do not frequently undertake restructuring initiatives and therefore do not consider such costs to be normal, recurring operating expenses.

 

Certain Other Items:  We exclude certain other significant items that may occur occasionally and are not normal, recurring cash operating expenses from our adjusted financial results. Such items are evaluated on an individual basis based on both the quantitative and the qualitative aspect of their nature and generally represent items that, either as a result of their nature or magnitude, we would not anticipate occurring as part of our normal business on a regular basis. While not all-inclusive, examples of certain other significant items excluded from adjusted financial results would be: significant litigation-related loss contingency accruals and expenses to settle other disputed matters and, effective for fiscal year 2018, changes in the fair value of our equity securities upon the adoption of ASU 2016-01 (Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities).

 

Estimated Tax Impact From Above Adjustments:  We exclude the net income tax impact of the non-tax adjustments described above from our adjusted financial results. The net income tax impact of the non-tax adjustments includes the impact on both current and deferred income taxes and is based on the taxability of the adjustment under local tax law and the statutory tax rate in the tax jurisdiction where the adjustment was incurred.

 

Non-Operating Tax Adjustments:  We exclude the net income tax impact of certain other significant income tax items, which are not associated with our normal, recurring operations (“Non-Operating Tax Items”), from our adjusted financial results. Non-Operating Tax Items include items which may occur occasionally and are not normal, recurring operating expenses (or benefits), including adjustments related to acquisitions, divestitures, collaborations, certain adjustments to the amount of unrecognized tax benefits related to prior year tax positions, the impact of tax reform legislation commonly referred to as the Tax Cuts and Jobs Act (2017 Tax Act), and other similar items. We also exclude excess tax benefits and tax deficiencies that arise upon vesting or exercise of share-based payments recognized as income tax benefits or expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing.

 

See the attached Reconciliations of GAAP to Adjusted Net Income for explanations of the amounts excluded and included to arrive at the adjusted measures for the three- and nine-month periods ended September 30, 2018 and 2017, and for the projected amounts for the twelve-month period ending December 31, 2018.

 



 

Celgene Corporation and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(In millions, except per share data)

 

 

 

Three-Month Periods Ended

 

Nine-Month Periods Ended

 

 

 

September 30,

 

September 30,

 

 

 

2018

 

2017

 

2018

 

2017

 

 

 

 

 

 

 

 

 

 

 

Net product sales

 

$

3,890

 

$

3,283

 

$

11,229

 

$

9,494

 

Other revenue

 

2

 

4

 

15

 

26

 

Total revenue

 

3,892

 

3,287

 

11,244

 

9,520

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold (excluding amortization of acquired intangible assets)

 

157

 

118

 

418

 

342

 

Research and development

 

1,081

 

1,347

 

4,535

 

3,177

 

Selling, general and administrative

 

746

 

608

 

2,400

 

2,167

 

Amortization of acquired intangible assets

 

127

 

80

 

341

 

250

 

Acquisition related charges and restructuring, net

 

101

 

49

 

166

 

75

 

Total costs and expenses

 

2,212

 

2,202

 

7,860

 

6,011

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

1,680

 

1,085

 

3,384

 

3,509

 

 

 

 

 

 

 

 

 

 

 

Interest and investment income, net

 

8

 

33

 

30

 

72

 

Interest (expense)

 

(193

)

(127

)

(551

)

(380

)

Other (expense) income, net

 

(117

)

 

852

 

(18

)

 

 

 

 

 

 

 

 

 

 

Income before income taxes

 

1,378

 

991

 

3,715

 

3,183

 

 

 

 

 

 

 

 

 

 

 

Income tax provision

 

296

 

3

 

742

 

162

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

1,082

 

$

988

 

$

2,973

 

$

3,021

 

 

 

 

 

 

 

 

 

 

 

Net income per common share:

 

 

 

 

 

 

 

 

 

Basic

 

$

1.54

 

$

1.26

 

$

4.12

 

$

3.87

 

Diluted

 

$

1.50

 

$

1.21

 

$

4.02

 

$

3.72

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares:

 

 

 

 

 

 

 

 

 

 

Basic

 

702.0

 

784.1

 

722.0

 

781.2

 

Diluted

 

719.7

 

815.2

 

740.4

 

812.6

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

 

 

 

 

 

2018

 

2017

 

 

 

 

 

Balance sheet items:

 

 

 

 

 

 

 

 

 

Cash, cash equivalents, debt securities available-for-sale and equity investments with readily determinable fair values

 

$

4,378

 

$

12,042

 

 

 

 

 

Total assets

 

34,215

 

30,141

 

 

 

 

 

Long-term debt, including current portion

 

20,244

 

15,838

 

 

 

 

 

Total stockholders’ equity

 

4,860

 

6,921

 

 

 

 

 

 


 

Celgene Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Net Income

(In millions, except per share data)

 

 

 

Three-Month Periods Ended

 

Nine-Month Periods Ended

 

 

 

September 30,

 

September 30,

 

 

 

2018

 

2017

 

2018

 

2017

 

 

 

 

 

 

 

 

 

 

 

Net income - GAAP

 

$

1,082

 

$

988

 

$

2,973

 

$

3,021

 

 

 

 

 

 

 

 

 

 

 

Before tax adjustments:

 

 

 

 

 

 

 

 

 

Cost of goods sold (excluding amortization of acquired intangible assets):

 

 

 

 

 

 

 

 

 

 

Share-based compensation expense

(1)

9

 

7

 

27

 

22

 

 

 

 

 

 

 

 

 

 

 

Research and development:

 

 

 

 

 

 

 

 

 

Share-based compensation expense

 

(1)

125

 

65

 

481

 

200

 

Collaboration-related upfront expense

(2)

8

 

584

 

399

 

669

 

Research and development asset acquisition expense

(3)

 

 

1,125

 

325

 

Adjustment to clinical trial and development activity wind-down charge

(4)

 

 

(60

)

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative:

 

 

 

 

 

 

 

 

 

Share-based compensation expense

(1)

104

 

87

 

415

 

260

 

Litigation-related loss contingency accrual expense

(5)

 

 

 

315

 

 

 

 

 

 

 

 

 

 

 

Amortization of acquired intangible assets

(6)

127

 

80

 

341

 

250

 

 

 

 

 

 

 

 

 

 

 

Acquisition related charges and restructuring, net:

 

 

 

 

 

 

 

 

 

Change in fair value of contingent consideration and success payments

(7)

97

 

49

 

74

 

75

 

Acquisition related charges

(8)

4

 

 

92

 

 

 

 

 

 

 

 

 

 

 

 

Other (expense) income, net:

 

 

 

 

 

 

 

 

 

Change in fair value of equity investments

(9)

123

 

 

(830

)

 

 

 

 

 

 

 

 

 

 

 

Income tax provision:

 

 

 

 

 

 

 

 

 

Estimated tax impact from above adjustments

(10)

(57

)

(149

)

(242

)

(387

)

Non-operating tax adjustments

(11)

23

 

(156

)

7

 

(326

)

Net income - Adjusted

 

$

1,645

 

$

1,555

 

$

4,802

 

$

4,424

 

 

 

 

 

 

 

 

 

 

 

Net income per common share - Adjusted

 

 

 

 

 

 

 

 

 

Basic

 

$

2.34

 

$

1.98

 

$

6.65

 

$

5.66

 

Diluted

 

$

2.29

 

$

1.91

 

$

6.49

 

$

5.44

 

 


Explanation of adjustments:

(1)             Exclude share-based compensation expense totaling $238 and $159 for the three-month periods ended September 30, 2018 and 2017, respectively. Exclude share-based compensation expense totaling $923 and $482 for the nine-month periods ended September 30, 2018 and 2017, respectively.

(2)             Exclude upfront payment expense for research and development collaboration arrangements.

(3)             Exclude research and development asset acquisition expenses.

(4)             Exclude adjustment of clinical trial and development activity wind-down charge associated with the discontinuance of GED-0301 clinical trials in Crohn’s disease.

(5)             Exclude loss contingency accrual expenses related to a civil litigation matter.

(6)             Exclude amortization of intangible assets acquired in the acquisitions of Pharmion Corp., Gloucester Pharmaceuticals, Inc. (Gloucester), Abraxis BioScience, Inc. (Abraxis), Celgene Avilomics Research, Inc. (Avila), Quanticel Pharmaceuticals, Inc. (Quanticel) and Juno Therapeutics, Inc. (Juno).

(7)             Exclude changes in the fair value of contingent consideration related to the acquisitions of Gloucester, Abraxis, Avila, Nogra Pharma Limited (Nogra), Quanticel and Juno, as well as changes in the fair value of success payments related to the acquisition of Juno.

(8)             Exclude acquisition costs related to Juno.

(9)             Exclude changes in the fair value of equity investments upon the adoption of ASU 2016-01 (Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities).

(10)      Exclude the estimated tax impact of the above adjustments.

(11)      Exclude other non-operating tax expense items. The adjustments for the three-month period ended September 30, 2018 are to exclude the excess tax benefits related to the adoption of ASU 2016-09 (Compensation-Stock Compensation) of $6, adjustments to the provisional amounts recorded for the one-time 2017 U.S. Transition Tax of $36 and to exclude other adjustments totaling tax benefit of $7. The adjustments for the nine-month period ended September 30, 2018 are to exclude the excess tax benefits related to the adoption of ASU 2016-09 (Compensation-Stock Compensation) of $22, adjustments to the provisional amounts recorded for the one-time 2017 U.S. Transition Tax of $36 and to exclude other adjustments totaling tax benefit of $7.

 

The adjustments for the three-month period ended September 30, 2017 are to exclude the excess tax benefits related to the adoption of ASU 2016-09 (Compensation-Stock Compensation) of $103, prior year tax benefits arising from a U.S. research and development and orphan drug tax credits study of $55 and to exclude other adjustments totaling tax expense of $2. The adjustments for the nine-month period ended September 30, 2017 are to exclude the excess tax benefits related to the adoption of ASU 2016-09 (Compensation-Stock Compensation) of $273, prior year tax benefits arising from a U.S. research and development and orphan drug tax credits study of $55 and to exclude other adjustments totaling tax expense of $2.

 


 

Celgene Corporation and Subsidiaries

Reconciliation of Full-Year 2018 Projected GAAP to Adjusted Net Income

(In millions, except per share data)

 

 

 

Range

 

 

 

Low

 

High

 

 

 

 

 

 

 

Projected net income - GAAP

(1)

$

3,857

 

$

4,228

 

 

 

 

 

 

 

Before tax adjustments:

 

 

 

 

 

Cost of goods sold (excluding amortization of acquired intangible assets):

 

 

 

 

 

Share-based compensation expense

 

33

 

27

 

 

 

 

 

 

 

Research and development:

 

 

 

 

 

Share-based compensation expense

 

586

 

471

 

Collaboration-related upfront expense

 

399

 

399

 

Research and development asset acquisition expense

 

 

1,125

 

1,125

 

Adjustment to clinical trial and development activity wind-down charge

 

(60

)

(60

)

 

 

 

 

 

 

Selling, general and administrative:

 

 

 

 

 

Share-based compensation expense

 

 

573

 

461

 

 

 

 

 

 

 

Amortization of acquired intangible assets

 

493

 

469

 

 

 

 

 

 

 

Acquisition related charges and restructuring, net:

 

 

 

 

 

Change in fair value of contingent consideration and success payments

 

83

 

32

 

Acquisition related charges

 

115

 

92

 

 

 

 

 

 

 

Other income (expense), net:

 

 

 

 

 

Change in fair value of equity investments

 

(490

)

(490

)

 

 

 

 

 

 

Income tax provision:

 

 

 

 

 

Estimated tax impact from above adjustments

 

(290

)

(293

)

Non-operating tax adjustments

 

7

 

7

 

Projected net income - Adjusted

 

$

6,431

 

$

6,468

 

 

 

 

 

 

 

Projected net income per diluted common share - GAAP

 

$

5.25

 

$

5.75

 

 

 

 

 

 

 

Projected net income per diluted common share - Adjusted

 

 

$

8.75

 

$

8.80

 

 

 

 

 

 

 

Projected weighted average diluted shares

 

735.0

 

735.0

 

 


(1)             Our projected 2018 earnings do not include the effect of any business combinations, collaboration agreements, asset acquisitions, asset impairments, litigation-related loss contingency accruals, changes in the fair value of our CVRs issued as part of the acquisition of Abraxis, changes in the fair value of equity investments upon the adoption of ASU 2016-01 (Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities) or non-operating tax adjustments that may occur after the day prior to the date of this press release.

 



 

Celgene Corporation and Subsidiaries

Net Product Sales

(In millions)

 

 

 

Three-Month Periods

 

 

 

Ended September 30,

 

% Change

 

 

 

2018

 

2017

 

Reported

 

Operational(1)

 

Currency(2)

 

 

 

 

 

 

 

 

 

 

 

 

 

REVLIMID®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

$

1,667

 

$

1,361

 

22.5

%

22.5

%

0.0

%

International

 

782

 

720

 

8.6

%

10.2

%

(1.6

)%

Worldwide

 

2,449

 

2,081

 

17.7

%

18.3

%

(0.6

)%

 

 

 

 

 

 

 

 

 

 

 

 

POMALYST®/IMNOVID®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

357

 

268

 

33.2

%

33.2

%

0.0

%

International

 

156

 

149

 

4.7

%

6.1

%

(1.4

)%

Worldwide

 

513

 

417

 

23.0

%

23.5

%

(0.5

)%

 

 

 

 

 

 

 

 

 

 

 

 

OTEZLA®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

348

 

250

 

39.2

%

39.2

%

0.0

%

International

 

84

 

58

 

44.8

%

45.7

%

(0.9

)%

Worldwide

 

432

 

308

 

40.3

%

40.5

%

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

ABRAXANE®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

174

 

149

 

16.8

%

16.8

%

0.0

%

International

 

114

 

102

 

11.8

%

12.4

%

(0.6

)%

Worldwide

 

288

 

251

 

14.7

%

14.9

%

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

IDHIFA® (3)

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

18

 

7

 

157.1

%

157.1

%

0.0

%

International

 

1

 

 

N/A

 

N/A

 

N/A

 

Worldwide

 

19

 

7

 

171.4

%

171.6

%

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

VIDAZA®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

2

 

1

 

100.0

%

100.0

%

0.0

%

International

 

137

 

150

 

(8.7

)%

(7.2

)%

(1.5

)%

Worldwide

 

139

 

151

 

(7.9

)%

(6.4

)%

(1.5

)%

 

 

 

 

 

 

 

 

 

 

 

 

azacitidine for injection

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

6

 

13

 

(53.8

)%

(53.8

)%

0.0

%

International

 

1

 

1

 

0.0

%

9.1

%

(9.1

)%

Worldwide

 

7

 

14

 

(50.0

)%

(49.5

)%

(0.5

)%

 

 

 

 

 

 

 

 

 

 

 

 

THALOMID®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

19

 

21

 

(9.5

)%

(9.5

)%

0.0

%

International

 

11

 

13

 

(15.4

)%

(13.2

)%

(2.2

)%

Worldwide

 

30

 

34

 

(11.8

)%

(11.0

)%

(0.8

)%

 

 

 

 

 

 

 

 

 

 

 

 

ISTODAX®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

9

 

17

 

(47.1

)%

(47.1

)%

0.0

%

International

 

4

 

2

 

100.0

%

102.0

%

(2.0

)%

Worldwide

 

13

 

19

 

(31.6

)%

(31.4

)%

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

All Other

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

 

1

 

N/A

 

N/A

 

N/A

 

International

 

 

 

N/A

 

N/A

 

N/A

 

Worldwide

 

 

1

 

N/A

 

N/A

 

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Product Sales

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

2,600

 

2,088

 

24.5

%

24.5

%

0.0

%

International

 

1,290

 

1,195

 

7.9

%

9.4

%

(1.5

)%

Worldwide

 

$

3,890

 

$

3,283

 

18.5

%

19.0

%

(0.5

)%

 


(1)         Operational includes impact from both volume and price.

(2)         Currency includes the impact from both foreign exchange rates and hedging activities.

(3)         IDHIFA® was approved in August 2017 in the U.S. for the treatment of adult patients with R/R AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test.

 


 

Celgene Corporation and Subsidiaries

Net Product Sales

(In millions)

 

 

 

Nine-Month Periods

 

 

 

Ended September 30,

 

% Change

 

 

 

2018

 

2017

 

Reported

 

Operational(1)

 

Currency(2)

 

 

 

 

 

 

 

 

 

 

 

 

 

REVLIMID®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

$

4,740

 

$

3,953

 

19.9

%

19.9

%

0.0

%

International

 

2,396

 

2,046

 

17.1

%

17.9

%

(0.8

)%

Worldwide

 

7,136

 

5,999

 

19.0

%

19.3

%

(0.3

)%

 

 

 

 

 

 

 

 

 

 

 

 

POMALYST®/IMNOVID®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

998

 

725

 

37.7

%

37.7

%

0.0

%

International

 

475

 

447

 

6.3

%

7.2

%

(0.9

)%

Worldwide

 

1,473

 

1,172

 

25.7

%

26.1

%

(0.4

)%

 

 

 

 

 

 

 

 

 

 

 

 

OTEZLA®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

915

 

755

 

21.2

%

21.2

%

0.0

%

International

 

245

 

153

 

60.1

%

60.6

%

(0.5

)%

Worldwide

 

1,160

 

908

 

27.8

%

27.9

%

(0.1

)%

 

 

 

 

 

 

 

 

 

 

 

 

ABRAXANE®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

485

 

452

 

7.3

%

7.3

%

0.0

%

International

 

308

 

289

 

6.6

%

7.2

%

(0.6

)%

Worldwide

 

793

 

741

 

7.0

%

7.2

%

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

IDHIFA® (3)

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

48

 

7

 

585.7

%

585.7

%

0.0

%

International

 

2

 

 

N/A

 

N/A

 

N/A

 

Worldwide

 

50

 

7

 

614.3

%

613.0

%

1.3

%

 

 

 

 

 

 

 

 

 

 

 

 

VIDAZA®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

7

 

5

 

40.0

%

40.0

%

0.0

%

International

 

451

 

460

 

(2.0

)%

(1.0

)%

(1.0

)%

Worldwide

 

458

 

465

 

(1.5

)%

(0.6

)%

(0.9

)%

 

 

 

 

 

 

 

 

 

 

 

 

azacitidine for injection

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

17

 

31

 

(45.2

)%

(45.2

)%

0.0

%

International

 

2

 

1

 

100.0

%

108.6

%

(8.6

)%

Worldwide

 

19

 

32

 

(40.6

)%

(40.4

)%

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

THALOMID®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

55

 

64

 

(14.1

)%

(14.1

)%

0.0

%

International

 

34

 

40

 

(15.0

)%

(13.8

)%

(1.2

)%

Worldwide

 

89

 

104

 

(14.4

)%

(14.0

)%

(0.4

)%

 

 

 

 

 

 

 

 

 

 

 

 

ISTODAX®

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

39

 

51

 

(23.5

)%

(23.5

)%

0.0

%

International

 

10

 

7

 

42.9

%

41.9

%

1.0

%

Worldwide

 

49

 

58

 

(15.5

)%

(15.6

)%

0.1

%

 

 

 

 

 

 

 

 

 

 

 

 

All Other

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

 

1

 

N/A

 

N/A

 

N/A

 

International

 

2

 

7

 

N/A

 

N/A

 

N/A

 

Worldwide

 

2

 

8

 

N/A

 

N/A

 

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Product Sales

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

7,304

 

6,044

 

20.8

%

20.8

%

0.0

%

International

 

3,925

 

3,450

 

13.8

%

14.8

%

(1.0

)%

Worldwide

 

$

11,229

 

$

9,494

 

18.3

%

18.6

%

(0.3

)%

 


(1)         Operational includes impact from both volume and price.

(2)         Currency includes the impact from both foreign exchange rates and hedging activities.

(3)         IDHIFA® was approved in August 2017 in the U.S. for the treatment of adult patients with R/R AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test.

 


View differences made from one to another to evaluate Celgene Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Celgene Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account